{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:37:27Z","timestamp":1760647047641},"publisher-location":"Cham","reference-count":52,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030203146"},{"type":"electronic","value":"9783030203153"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-030-20315-3_11","type":"book-chapter","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T05:05:44Z","timestamp":1563339944000},"page":"159-178","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms"],"prefix":"10.1007","author":[{"given":"Kamya","family":"Sankar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brady L.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"issue":"13","key":"11_CR1","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T. Barbui","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122(13):2176\u20132184","journal-title":"Blood"},{"issue":"5","key":"11_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"Ayalew Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29(5):573\u2013582","journal-title":"Journal of Clinical Oncology"},{"key":"11_CR3","doi-asserted-by":"crossref","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW, Landgren O, Derolf \u00c5R, Kristinsson SY, Andersson TML (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. [Epub ahead of print 16 January 2018]","DOI":"10.7326\/M17-0028"},{"issue":"10","key":"11_CR4","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"Roberto Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224\u20132232","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"11_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-2007-976165","volume":"33","author":"Ayalew Tefferi","year":"2007","unstructured":"Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33:313\u2013320","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"11_CR6","unstructured":"McMahon B, Stein BL (2013) Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost 39(1):101\u2013111"},{"issue":"4","key":"11_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1600-0609.2006.00715.x","volume":"77","author":"Naseema Gangat","year":"2006","unstructured":"Gangat et al (2006) Abdominal vein thrombosis in ET: prevalence, clinical correlates and prognostic implications. Eur J Haematol 77:323\u2013333","journal-title":"European Journal of Haematology"},{"issue":"25","key":"11_CR8","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","volume":"120","author":"J. H. Smalberg","year":"2012","unstructured":"Smalberg et al (2012) Myeloproliferative neoplasms in Budd-Chiari Syndrome and portal vein thrombosis: a meta-analysis. Blood 120(25):4921\u20134928","journal-title":"Blood"},{"issue":"22","key":"11_CR9","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A. Carobbio","year":"2011","unstructured":"Carobbio et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117(22):5857\u20135859","journal-title":"Blood"},{"issue":"9","key":"11_CR10","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","volume":"54","author":"Brady L. Stein","year":"2013","unstructured":"Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR (2013) Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma 54(9):1989\u20131995","journal-title":"Leukemia & Lymphoma"},{"key":"11_CR11","doi-asserted-by":"crossref","unstructured":"Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR (2011) Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis (article ID 874146)","DOI":"10.1155\/2011\/874146"},{"issue":"26","key":"11_CR12","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T. Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of Thrombosis in WHO-ET (IPSET-Thrombosis). Blood 120(26):5128\u20135133","journal-title":"Blood"},{"issue":"6","key":"11_CR13","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R. Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R (2007) Leukocytosis as a major thrombotic risk factor in patients with PV. Blood 109(6):2446\u20132452","journal-title":"Blood"},{"key":"11_CR14","doi-asserted-by":"crossref","unstructured":"Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A (2017) The effect of arterial hypertension in low-risk polycythemia vera. Am J of Hematology 92(1):E5","DOI":"10.1002\/ajh.24583"},{"issue":"4","key":"11_CR15","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T. Barbui","year":"2009","unstructured":"Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larr\u00e1n A, Rambaldi A, Finazzi G, Barosi G (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778\u2013782","journal-title":"Blood"},{"key":"11_CR16","doi-asserted-by":"crossref","unstructured":"Barbui T et al (2009) Perspective on thrombosis in essential thrombocythemia: is leukocytosis a causative factor? Blood 114:759\u2013763","DOI":"10.1182\/blood-2009-02-206797"},{"issue":"7","key":"11_CR17","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/jth.12967","volume":"13","author":"S. Lancellotti","year":"2015","unstructured":"Lancellotti S, Dragani A, Ranalli P, Petrucci G, Basso M, Tartaglione R, Rocca B, De Cristofaro R (2015) Qualitative and quantitative modifications of vWF In patients with ET and controlled platelet count. J Thromb Haemost 13:1226\u20131237","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"11_CR18","doi-asserted-by":"crossref","unstructured":"van Genderen PJ, Budde U, Michiels JJ, van Strik R, van Vliet HH (1996) The reduction of large vWF multimers in plasma in ET is related to platelet count. Br J Haematol 93:962\u2013965","DOI":"10.1046\/j.1365-2141.1996.d01-1729.x"},{"issue":"25","key":"11_CR19","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"Thorsten Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant\u2019Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Sch\u00f6negger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2380\u20132390","journal-title":"New England Journal of Medicine"},{"key":"11_CR20","doi-asserted-by":"crossref","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant\u2019antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M (2014) Jak2 or CALR mutation status defines subtypes of ET with substantially different clinical courses and outcomes. Blood 123(10):1544\u20131551","DOI":"10.1182\/blood-2013-11-539098"},{"key":"11_CR21","doi-asserted-by":"crossref","unstructured":"Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, Fabris F, Randi ML (2016) Thrombotic risk correlates with mutational status in ET. Eur J Clin Inv 46(8):683\u2013689","DOI":"10.1111\/eci.12647"},{"issue":"9","key":"11_CR22","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"A M Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T (2007) Prospective identification of high-risk polycythemia vera patients based on Jak2V617F allele burden. Leukemia 21:1952\u20131959","journal-title":"Leukemia"},{"issue":"7","key":"11_CR23","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E. Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Mart\u00ednez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M (2014) Clinical effect of driver mutations of JAK2, CALR, and MPL in primary myelofibrosis. Blood 24(7):1062\u20131069","journal-title":"Blood"},{"issue":"2","key":"11_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"Siddhartha Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL (2017) Clonal Hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377(2):111\u2013121","journal-title":"New England Journal of Medicine"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","volume":"85","author":"Federico Lussana","year":"2017","unstructured":"Lussana F, Rambaldi A (2017) Inflammation and myeloproliferative neoplasms. J Autoimmun 85:58\u201363","journal-title":"Journal of Autoimmunity"},{"key":"11_CR26","doi-asserted-by":"crossref","unstructured":"Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A (2017) Driver mutations, pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol 10:54","DOI":"10.1186\/s13045-017-0425-z"},{"key":"11_CR27","doi-asserted-by":"crossref","unstructured":"Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of CRP and pentraxin 3. Hematologica 96(2):315\u2013318","DOI":"10.3324\/haematol.2010.031070"},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1100\/tsw.2011.108","volume":"11","author":"Fabrizio Vianello","year":"2011","unstructured":"Vianello F, Battisti A, Cella G, Marchetti M, Falanga A (2011) Defining the thrombotic risk in patients with myeloproliferative neoplasms. Sci World J 11:1131\u20131137","journal-title":"The Scientific World JOURNAL"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","volume":"2012","author":"A Falanga","year":"2012","unstructured":"Falanga A et al (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012:571\u2013581","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"2","key":"11_CR30","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3892\/ol.2017.6459","volume":"14","author":"Wenjuan Zhang","year":"2017","unstructured":"Zhang W, Qi J, Zhao S, Shen W, Dai L, Han W, Huang M, Wang Z, Ruan C, Wu D, Han Y (2017) Clinical significance of circulating microparticles in Ph-myeloproliferative neoplasms. Oncol Lett 14:2531\u20132536","journal-title":"Oncology Letters"},{"issue":"10","key":"11_CR31","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1182\/blood-2008-06-164087","volume":"112","author":"M. Marchetti","year":"2008","unstructured":"Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A (2008) Thrombin generation and APC resistance in patients with ET and PV. Blood 112(1):4061\u20134068","journal-title":"Blood"},{"key":"11_CR32","unstructured":"Tevet M, Ionescu R, Dragan C, Lupu AR (2015) Influence of the Jak2V617F mutation and inherited thrombophilia on the thrombotic risk among patients with myeloproliferative disorders. Maedica 10(1):27\u201332"},{"issue":"4","key":"11_CR33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","volume":"91","author":"Mahnur Haider","year":"2016","unstructured":"Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, Tefferi A (2016) Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol 91(4):390\u2013394","journal-title":"American Journal of Hematology"},{"issue":"6","key":"11_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"Tiziano Barbui","year":"2011","unstructured":"Barbui et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J Clin Oncol 29(6):761\u2013769","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"11_CR35","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881","journal-title":"Leukemia"},{"issue":"5","key":"11_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.patbio.2004.02.007","volume":"52","author":"Guido Finazzi","year":"2004","unstructured":"Finazzi G (2004) A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol (Paris) 52:285\u2013288","journal-title":"Pathologie Biologie"},{"issue":"2","key":"11_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"Raffaele Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350(2):114\u2013124","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"11_CR38","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"J.-J. Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematologic molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065\u20133072","journal-title":"Blood"},{"key":"11_CR39","unstructured":"Gisslinger H, Zagrijtschuk O, Veronika B-A, Thaler J, Schloegl E, Guenther A. Gastl, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Nicole C. Them, Kadlecova P, Klade C, Greil R (2017) Ropeginterferon Alfa-2b Induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized control trial. In: The 59th annual meeting & exposition of the American Society of Hematology, Atlanta, GA, 9\u201312 Dec 2017. (Abstract nr 320)"},{"key":"11_CR40","doi-asserted-by":"crossref","unstructured":"Vannucchi AM (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435","DOI":"10.1056\/NEJMoa1409002"},{"issue":"8","key":"11_CR41","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3324\/haematol.2016.146654","volume":"101","author":"A. Alvarez-Larran","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Guglielmelli P, Hern\u00e1ndez-Boluda JC, Arellano-Rodrigo E, Ferrer-Mar\u00edn F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, Garc\u00eda-Guti\u00e9rrez V, Ayala R, Barba P, G\u00f3mez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C (2016) Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 101(8):926\u2013931","journal-title":"Haematologica"},{"issue":"8","key":"11_CR42","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","volume":"116","author":"A. Alvarez-Larran","year":"2010","unstructured":"Alvarez-Larran et al (2010) Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116(8):1205\u20131210","journal-title":"Blood"},{"issue":"3","key":"11_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7326\/M17-0284","volume":"167","author":"Derek K. Chu","year":"2017","unstructured":"Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM (2017) Benefits and risks of antithrombotic therapy in essential thrombocythemia. Ann Intern Med 167:170\u2013180","journal-title":"Annals of Internal Medicine"},{"issue":"17","key":"11_CR44","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"Sergio Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332(17):1132\u20131136","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"11_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"Claire N. Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) Hydroxyurea compared with anagrelide in high-risk ET. N Engl J Med 353(1):33\u201345","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"11_CR46","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H. Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized control trial. Blood 121(10):1720\u20131728","journal-title":"Blood"},{"issue":"17","key":"11_CR47","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","volume":"130","author":"Claire N. Harrison","year":"2017","unstructured":"Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF (2017) Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 130(17):1889\u20131897","journal-title":"Blood"},{"issue":"2","key":"11_CR48","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.thromres.2014.04.032","volume":"134","author":"Martin H. Ellis","year":"2014","unstructured":"Ellis MH, Lavi N, Vannucchi A, Harrison C (2014) Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. Thromb Res 134:251\u2013254","journal-title":"Thrombosis Research"},{"issue":"4","key":"11_CR49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12185-017-2282-5","volume":"106","author":"Jean-Christophe Ianotto","year":"2017","unstructured":"Ianotto et al (2017) Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol 106:517\u2013521","journal-title":"International Journal of Hematology"},{"key":"11_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.leukres.2017.03.008","volume":"58","author":"Prajwal Boddu","year":"2017","unstructured":"Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S (2017) The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: a case-based review. Leuk Res 58:14\u201322","journal-title":"Leukemia Research"},{"issue":"5_suppl","key":"11_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/039139889301605s40","volume":"16","author":"R. Adami","year":"1993","unstructured":"Adami R (1993) Therapeutic thrombocytapheresis: a review of 132 patients. Int J Artif Organs 16(Suppl. 5):183\u2013184","journal-title":"The International Journal of Artificial Organs"},{"issue":"2","key":"11_CR52","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood-2007-07-102665","volume":"111","author":"M. Ruggeri","year":"2008","unstructured":"Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, Delaini F, Mic\u00f2 C, Vannucchi AM, Antonioli E, De Stefano V, Za T, Gugliotta L, Tieghi A, Mazzucconi MG, Santoro C, Barbui T (2008) Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111:666\u2013671","journal-title":"Blood"}],"container-title":["Cancer Treatment and Research","Thrombosis and Hemostasis in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-20315-3_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T02:03:05Z","timestamp":1575424985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-20315-3_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030203146","9783030203153"],"references-count":52,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-20315-3_11","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"type":"print","value":"0927-3042"},{"type":"electronic","value":"2509-8497"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"18 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}